Nachrichten zur Hims & Hers Health Inc. Aktie

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The…

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the…

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the…

Hims & Hers Health stock has delivered a very large 5 year gain, yet the latest valuation work suggests the…

Hims & Hers Health Inc (HIMS) Analyst Rating Update On July 24, 2026, Truist Securities announced it…

On July 24, 2026, Hims & Hers Health (HIMS) experienced a decline of over 11% following an unfavorable decision from…

Hims & Hers (HIMS) stock slides after an FDA advisory panel for the first time in a two-day meeting declines…

On July 24, 2026, Hims & Hers Health Inc (HIMS) experienced a notable decline in its stock price, dropping by…

Hims & Hers Health, Inc. (HIMS) is down 10.4% today. Here is some analysis on what might have caused this…

Hims & Hers stock is upgraded to "Buy" given its upside potential. Heres what investors need to know.…

Hims & Hers (HIMS) is down -10.3%, or -$3.38 to $29.36. Published first on TheFly – the ultimate source for…

What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured…

What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured…

Ich halte die Euphorie um Hims & Hers für verfrüht. Acht Ja-Stimmen gegen sechs Nein-Stimmen bei einer Enthaltung – mit…

Eine 8-zu-6-Empfehlung ist keine Zulassung. Die FDA-Berater öffnen Peptide wie BPC-157 für die Apothekenherstellung, doch die Behörde muss erst ein…

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the…

Hims & Hers Health is in focus Friday after an FDA advisory panel on Thursday recommended adding four peptides to…

Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable - TechStock²…

Telehealth companies including Hims & Hers Health Inc. and Noom Inc. urged a panel of experts to recommend legalizing several…

Earlier in July 2026, Hims & Hers Health announced that Chief Accounting Officer and Principal Accounting Officer Irene Becklund will…

In July 2026, an FDA advisory committee recommended easing compounding restrictions on several peptides, including BPC-157, while Hims & Hers…

Hims & Hers Health has been upgraded from Hold to Buy due to its disciplined operations and strategic growth in…

Hims & Hers Health (HIMS) is back in focus after an FDA advisory panel recommended allowing broader compounding of peptide…

On July 23, 2026, Hims & Hers Health Inc (HIMS) shares rose 3.4% today, closing at $32.74. The stock has…

Hims and Hers stock gains on peptide compounding vote outlook…

Hims and Hers stock gains on peptide compounding vote outlook…

Hims & Hers Health Analyst Rating Update On July 23, 2026, Citigroup maintained a Neutral rating on…

Why is Hims & Hers Health stock rallying today?…

Explore Hims & Hers Health, Inc. stock analysis amid FDA catalyst and neutral technical signals. Understand the key price levels…

On July 23, 2026, Hims & Hers Health Inc (HIMS) saw its stock price increase by more than 10% after…

Hims & Hers Health (HIMS) stock rises as an FDA panel backs placing popular peptide BPC-157 in a list compounding…